CJC-1295 DAC is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
CJC-1295 DAC is being researched for sleep applications. Binds GHRH receptors on pituitary somatotrophs to stimulate GH synthesis and secretion. The DAC module covalently binds to endogenous albumin, extending the half-life to 6-8 days while maintaining rec. Common dosages for this use range from 1-2 mg per injection once or twice weekly.
Can CJC-1295 DAC Help With Sleep?
CJC-1295 DAC (CJC-1295 with Drug Affinity Complex) is being researched for sleep applications based on its mechanism as a GHRH analog with extended half-life.
Binds GHRH receptors on pituitary somatotrophs to stimulate GH synthesis and secretion. The DAC module covalently binds to endogenous albumin, extending the half-life to 6-8 days while maintaining receptor bioavailability. This creates sustained, elevated GH levels rather than the pulsatile release seen with CJC-1295 no DAC.
What Does the Research Show for CJC-1295 DAC and Sleep?
Single dose increases plasma GH 2-10 fold for 6+ days and IGF-1 0.5-3 fold for 9-11 days in humans. Multiple clinical trials demonstrated sustained dose-dependent GH/IGF-1 elevation. Reached Phase II before discontinuation.
The relevance to sleep specifically comes from CJC-1295 DAC's effects on sustained GH elevation, elevated IGF-1 levels, enhanced protein synthesis, improved body composition, increased muscle mass.
What Protocol Is Used for Sleep?
For sleep applications, the standard CJC-1295 DAC protocol is 1-2 mg per injection administered once or twice weekly via subcutaneous injection for 12-16 weeks.
Some researchers adjust dosing based on the specific sleep application — see our CJC-1295 DAC dosage guide for full protocol details.
Can Stacking Improve Sleep Results?
Synergizes with GHRP-6 or GHRP-2 for amplified GH pulse amplitude. The sustained release makes it less ideal for stacking than CJC-1295 no DAC, which preserves natural pulsatility.
What Side Effects Apply to Sleep Use?
Water retention, joint aches, fluid retention, mild headache. Sustained GH elevation may cause more pronounced side effects than pulsatile release versions. One subject death in Phase II trial was attributed to unrelated coronary artery disease.
Side effects are generally consistent regardless of the specific application. See our CJC-1295 DAC side effects guide for details.
Calculate Your CJC-1295 DAC Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for CJC-1295 DAC.
Open Calculator →Bottom Line: CJC-1295 DAC for Sleep
CJC-1295 DAC shows preliminary research potential for sleep. Standard protocols (1-2 mg per injection, once or twice weekly, 12-16 weeks) apply.
Source from COA-tested vendors and maintain consistent dosing for the full cycle duration.
Complete Guide
CJC-1295 DAC : Benefits, Dosage, Side Effects & Research
Related Reading
- CJC-1295 DAC Dosage Guide
- CJC-1295 DAC Benefits
- CJC-1295 DAC Side Effects
- CJC-1295 DAC Stacking Guide
- CJC-1295 DAC Cycle Guide
- CJC-1295 DAC Research
Research-Grade Sourcing
If you're going to research CJC-1295 DAC, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is CJC-1295 DAC?
CJC-1295 DAC (CJC-1295 with Drug Affinity Complex) is a GHRH analog with extended half-life. Synthetic GHRH analog with four amino acid substitutions conjugated to a drug affinity complex that binds endogenous albumin. It is researched for sustained GH elevation, elevated IGF-1 levels, enhanced protein synthesis, improved body composition, increased muscle mass.
What is the recommended CJC-1295 DAC dosage?
Common dosages: 1-2 mg per injection administered once or twice weekly via subcutaneous injection. Cycle length: 12-16 weeks. Half-life: 6-8 days. Use our peptide calculator for exact reconstitution math.
What are the side effects of CJC-1295 DAC?
Water retention, joint aches, fluid retention, mild headache. Sustained GH elevation may cause more pronounced side effects than pulsatile release versions. One subject death in Phase II trial was attributed to unrelated coronary artery disease.
Is CJC-1295 DAC safe?
CJC-1295 DAC has shown a preliminary safety profile in research. Not FDA-approved. Development discontinued post-Phase II. WADA banned. Available as research peptide. All research should follow appropriate safety protocols.